Donafinil toluenesulfonate, a new chemical antitumor drug of Zejing biological 1.1, landed in Kunshan

A new anti-tumor drug with independent intellectual property rights will be launched in Suzhou Yesterday, Sheng Zelin, general manager of Suzhou Zejing biopharmaceutical Co., Ltd., announced the good news This class 1.1 chemical anti-tumor drug, donafinil toluene sulfonate, has a significant therapeutic effect on advanced liver cancer, colorectal cancer, advanced renal cancer, thyroid cancer and acute myeloid leukemia, and has entered phase II / III clinical trials It is understood that Zejing is studying more than 8 innovative drugs with independent intellectual property rights Among the innovative drugs under study, the new chemical drugs zg0128, zg0320 and zg0529 are special new drugs for the treatment of primary myelofibrosis, rheumatoid arthritis, non-small cell lung cancer and chronic lymphocytic leukemia, which are all in urgent need in China Zejing's new biological drugs, such as recombinant human thrombin, recombinant human coagulation factor VIIa, are mainly used in the treatment of hemophilia, surgical bleeding, internal bleeding and other bleeding of various reasons, filling the domestic gap "The investment risk in the field of biomedicine is large, first, because of the high content of science and technology and the need for more investment; second, because of the long research and development cycle and the need for a long-term perspective, it is doomed that the entrepreneurial difficulty coefficient in this field is greater than that in many industries." Sheng said Zejing is located in the small nucleic acid industry base of Kunshan high tech Zone At present, 50% of the R & D team of the company has a master's degree or above The company has unique advantages and rich experience in new drug research and development, clinical trials, drug production and quality control, enterprise management and other fields The R & D center is equipped with international advanced R & D equipment, and shares the base platform facilities and equipment It is understood that in 2016, Zejing will continue to improve the industrial system, complete the construction of 11000 square meters of chemical preparations and 4000 square meters of recombinant protein drug production facilities and GMP (quality management standard for drug production) decoration, and complete the construction of GMP documents and management system The completion of these two industrial production lines and systems will become a demonstration GMP production line of Kunshan biomedical industrial park, and will take the lead in the production and marketing of class 1.1 new anti-tumor drugs and recombinant protein drugs Sheng Zelin said that Zejing is a local growing enterprise in Kunshan In March 2009, he led his team to Kunshan high tech Zone and founded Suzhou Zejing biopharmaceutical Co., Ltd., whose main business is the research and development and industrialization of innovative drugs In the past seven years, Zejing has made outstanding achievements in new drug research and development and company operation Zejing has successively obtained the National Innovation Fund for small and medium-sized enterprises, 3 National 12.5 major science and technology projects, a number of provincial projects in Jiangsu Province, and applied for 62 invention patents, 25 of which have been authorized by the United States, the European Union, China and other countries In the near future, Zejing will introduce 120 million yuan of venture capital to promote the industrialization of new drugs.